Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD


June 24, 2021

Zhou and colleagues showed that the A1c-lowering efficacy of SGLT2 inhibitors plus DPP-4 inhibitors is higher in Asian patients than in other ethnic groups. It is possible that the differences in body mass index across ethnic groups may moderate this effect. Asian patients with type 2 diabetes have lower body mass index, higher amounts of visceral fat, and a predominant insulin secretory defect compared with Western patients, whose insulin secretion capacity and insulin resistance are usually greater. The authors theorize that the GLP-1 deficiency together with the beta-cell dysfunction in Asian patients plays a major role in their superior response to incretin-based drugs.

Learn more about pharmacologic therapy in type 2 diabetes.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: